Evaluation of the influence of the conjugation site of the chelator agent HYNIC to GLP1 antagonist radiotracer for insulinoma diagnosis

dc.creatorFAINTUCH, BLUMA L.
dc.creatorSEO, DANIELE
dc.creatorOLIVEIRA, ERICA A. de
dc.creatorTARGINO, ROSELAINE C.
dc.creatorMORO, ANA M.
dc.date2017
dc.date2017-08-14T17:09:36Z
dc.date2017-08-14T17:09:36Z
dc.date.accessioned2023-09-28T13:34:44Z
dc.date.available2023-09-28T13:34:44Z
dc.identifier1874-4729
dc.identifierhttp://repositorio.ipen.br/handle/123456789/27705
dc.identifier1
dc.identifier10
dc.identifier10.2174/1874471010666170126143636
dc.identifier
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8997966
dc.descriptionBackground and Objective: Radiotracer diagnosis of insulinoma, can be done using somatostatin or glucagon-like peptide 1 (GLP-1). Performance of GLP-1 antagonists tends to be better than of agonists. Methods: We investigated the uptake of the antagonist exendin (9-39), radiolabeled with technetium-99m. Two different sites of the biomolecule were selected for chelator attachment. Results: HYNIC-beta Ala chelator attached to serine (C-terminus) of exendin, was associated with higher tumor uptake than to aspartate (N-terminus). Conclusion: The chelator position in the biomolecule influenced receptor uptake.
dc.format65-72
dc.relationCurrent Radiopharmaceuticals
dc.rightsclosedAccess
dc.subjecttracer techniques
dc.subjectinsulin
dc.subjectglucagon
dc.subjectpeptide hormones
dc.subjecttechnetium 99
dc.titleEvaluation of the influence of the conjugation site of the chelator agent HYNIC to GLP1 antagonist radiotracer for insulinoma diagnosis
dc.typeArtigo de peri??dico
dc.coverageI


Este ítem pertenece a la siguiente institución